Aberrant methylation of TRIM58 in hepatocellular carcinoma and its potential clinical implication

Qiu,Xueping; Huang,Yifang; Zhou,Ye; Zheng,Fang

doi:10.3892/or.2016.4871

Aberrant methylation of TRIM58 in hepatocellular carcinoma and its potential clinical implication

Authors:
- Xueping Qiu
- Yifang Huang
- Ye Zhou
- Fang Zheng
View Affiliations

Affiliations: Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China
Published online on: June 13, 2016 https://doi.org/10.3892/or.2016.4871
Pages: 811-818

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

TRIM58 (tripartite motif containing 58) has been reported as a novel methylated gene in hepatocellular carcinoma (HCC) by methylation microarrays. However, its associations with mRNA expression and clinicopathological characteristics have not been evaluated. In this study, we explored the potential clinical implications of TRIM58 methylation in HCC. We analyzed the methylation level of TRIM58 in 181 HCC tissues, 172 matched adjacent non-tumor tissues and 13 normal liver tissues using methylation-sensitive restriction enzyme based quantitative PCR and bisulfite genomic sequencing. Further, the mRNA expression level of TRIM58 was measured in 46 paired HCC and adjacent non-tumor tissues by quantitative real-time PCR. Moreover, the relationship between TRIM58 methylation and mRNA expression, the clinicopathological features, as well as prognostic value were evaluated. The results showed that TRIM58 methylation was significantly higher in HCC tissues compared with adjacent non-tumor tissues and normal liver tissues (both p<0.0001). Using 10% as the cut-off value, hypermethylation of TRIM58 was specific in HCC tissues (28.18%, 51/181), with a tendency to correlate with unfavorable disease-free survival (p=0.047). Moreover, TRIM58 expression was significantly decreased in HCC tissues compared with adjacent non-tumor tissues (p<0.0001), and showed a negative association with DNA methylation (p=0.015, rs= -0.260). Our data indicate that TRIM58 methylation is a common event in HCC and may contribute to downregulation of its mRNA expression. Furthermore, hypermethylation of TRIM58 tends to be associated with worse DFS after hepatectomy. However, the potential clinical application of TRIM58 need to be further investigated.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 142:1264–1273.e1. 2012. View Article : Google Scholar : PubMed/NCBI
3	Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
4	Shibata T and Aburatani H: Exploration of liver cancer genomes. Nat Rev Gastroenterol Hepatol. 11:340–349. 2014. View Article : Google Scholar : PubMed/NCBI
5	Pogribny IP and Rusyn I: Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett. 342:223–230. 2014. View Article : Google Scholar :
6	You JS and Jones PA: Cancer genetics and epigenetics: Two sides of the same coin? Cancer Cell. 22:9–20. 2012. View Article : Google Scholar : PubMed/NCBI
7	Um TH, Kim H, Oh BK, Kim MS, Kim KS, Jung G and Park YN: Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepato-carcinogenesis. J Hepatol. 54:939–947. 2011. View Article : Google Scholar
8	Raggi C and Invernizzi P: Methylation and liver cancer. Clin Res Hepatol Gastroenterol. 37:564–571. 2013. View Article : Google Scholar : PubMed/NCBI
9	Mikeska T, Bock C, Do H and Dobrovic A: DNA methylation biomarkers in cancer: Progress towards clinical implementation. Expert Rev Mol Diagn. 12:473–487. 2012. View Article : Google Scholar : PubMed/NCBI
10	Sceusi EL, Loose DS and Wray CJ: Clinical implications of DNA methylation in hepatocellular carcinoma. HPB Oxf. 13:369–376. 2011. View Article : Google Scholar
11	Napolitano LM and Meroni G: TRIM family: Pleiotropy and diversification through homomultimer and heteromultimer formation. IUBMB Life. 64:64–71. 2012. View Article : Google Scholar
12	Thom CS, Traxler EA, Khandros E, Nickas JM, Zhou OY, Lazarus JE, Silva AP, Prabhu D, Yao Y, Aribeana C, et al: Trim58 degrades Dynein and regulates terminal erythropoiesis. Dev Cell. 30:688–700. 2014. View Article : Google Scholar : PubMed/NCBI
13	Tao R, Li J, Xin J, Wu J, Guo J, Zhang L, Jiang L, Zhang W, Yang Z and Li L: Methylation profile of single hepatocytes derived from hepatitis B virus-related hepatocellular carcinoma. PLoS One. 6:e198622011. View Article : Google Scholar : PubMed/NCBI
14	Qiu X, Hu B, Huang Y, Deng Y, Wang X and Zheng F: Hypermethylation of ACP1, BMP4, and TSPYL5 in hepato-cellular carcinoma and their potential clinical significance. Dig Dis Sci. 61:149–157. 2016. View Article : Google Scholar
15	Zhang X, Liu S, Shen C, Wu Y, Zhang L, Chen X and Lu F: DNA methylation consistency implicates the primary tumor cell origin of recurrent hepatocellular carcinoma. Epigenomics. 7:581–592. 2015. View Article : Google Scholar : PubMed/NCBI
16	Wang Y, Cheng J, Xu C, Liu S, Jiang S, Xu Q, Chen X, Zhuang H and Lu F: Quantitative methylation analysis reveals gender and age differences in p16INK4a hypermethylation in hepatitis B virus-related hepatocellular carcinoma. Liver Int. 32:420–428. 2012.
17	Zhang X, Wang J, Cheng J, Ding S, Li M, Sun S, Zhang L, Liu S, Chen X, Zhuang H, et al: An integrated analysis of SOCS1 down-regulation in HBV infection-related hepatocellular carcinoma. J Viral Hepat. 21:264–271. 2014. View Article : Google Scholar :
18	Gao XD, Qu JH, Chang XJ, Lu YY, Bai WL, Wang H, Xu ZX, An LJ, Wang CP, Zeng Z, et al: Hypomethylation of long interspersed nuclear element-1 promoter is associated with poor outcomes for curative resected hepatocellular carcinoma. Liver Int. 34:136–146. 2014. View Article : Google Scholar :
19	Villanueva A, Portela A, Sayols S, Battiston C, Hoshida Y, Méndez-González J, Imbeaud S, Letouzé E, Hernandez-Gea V, Cornella H, et al HEPTROMIC Consortium: DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. Hepatology. 61:1945–1956. 2015. View Article : Google Scholar : PubMed/NCBI
20	Mah WC, Thurnherr T, Chow PK, Chung AY, Ooi LL, Toh HC, Teh BT, Saunthararajah Y and Lee CG: Methylation profiles reveal distinct subgroup of hepatocellular carcinoma patients with poor prognosis. PLoS One. 9:e1041582014. View Article : Google Scholar : PubMed/NCBI
21	Yan T, Zhao JJ, Bi XY, Zhao H, Huang Z, Li ZY, Zhou JG, Li Y, Li C, Cai JQ, et al: Prognosis of hepatocellular carcinoma: A study of 832 cases. Zhonghua Zhong Liu Za Zhi. 35:54–58. 2013.In Chinese. PubMed/NCBI
22	Tandon P and Garcia-Tsao G: Prognostic indicators in hepato-cellular carcinoma: a systematic review of 72 studies. Liver Int. 29:502–510. 2009. View Article : Google Scholar : PubMed/NCBI
23	Lu W, Dong J, Huang Z, Guo D, Liu Y and Shi S: Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection: Okuda, CLIP, TNM and CUPI. J Gastroenterol Hepatol. 23:1874–1878. 2008. View Article : Google Scholar : PubMed/NCBI
24	Fukushige S and Horii A: DNA methylation in cancer: A gene silencing mechanism and the clinical potential of its biomarkers. Tohoku J Exp Med. 229:173–185. 2013. View Article : Google Scholar : PubMed/NCBI
25	Gan L, Chen S, Zhong J, Wang X, Lam EK, Liu X, Zhang J, Zhou T, Yu J, Si J, et al: ZIC1 is downregulated through promoter hypermethylation, and functions as a tumor suppressor gene in colorectal cancer. PLoS One. 6:e169162011. View Article : Google Scholar : PubMed/NCBI
26	Zhong S, Tang MW, Yeo W, Liu C, Lo YM and Johnson PJ: Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas. Clin Cancer Res. 8:1087–1092. 2002.PubMed/NCBI
27	Kaur P, Mani S, Cros MP, Scoazec JY, Chemin I, Hainaut P and Herceg Z: Epigenetic silencing of sFRP1 activates the canonical Wnt pathway and contributes to increased cell growth and proliferation in hepatocellular carcinoma. Tumour Biol. 33:325–336. 2012. View Article : Google Scholar : PubMed/NCBI
28	He G, Hu S, Zhang D, Wu P, Zhu X, Xin S, Lu G, Ding Y and Liang L: Hypermethylation of FOXD3 suppresses cell proliferation, invasion and metastasis in hepatocellular carcinoma. Exp Mol Pathol. 99:374–382. 2015. View Article : Google Scholar : PubMed/NCBI
29	Shin SH, Lee KH, Kim BH, Lee S, Lee HS, Jang JJ and Kang GH: Downregulation of spleen tyrosine kinase in hepatocellular carcinoma by promoter CpG island hypermethylation and its potential role in carcinogenesis. Lab Invest. 94:1396–1405. 2014. View Article : Google Scholar : PubMed/NCBI
30	Xu X, Liu RF, Wan BB, Xing WM, Huang J and Han ZG: Expression of a novel gene FAM43B repressing cell proliferation is regulated by DNA methylation in hepatocellular carcinoma cell lines. Mol Cell Biochem. 354:11–20. 2011. View Article : Google Scholar : PubMed/NCBI